Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 15/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.63 |
| ▸ | RAD52 | P43351 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131168 | 1.00 | QPCT (1.00) | QPCTRXFP1RAD52ALDH1A1LMNA | |
| SCHEMBL5126287 | 0.99 | QPCT (1.00) | QPCTRXFP1RAD52 | |
| SCHEMBL3640500 | 0.97 | QPCT (1.00) | QPCTRXFP1RAD52 | |
| SCHEMBL5130634 | 0.85 | QPCT (1.00) | QPCTRXFP1 | |
| SCHEMBL3635273 | 0.83 | QPCT (1.00) | QPCTRXFP1RAD52ALDH1A1LMNA | |
| SCHEMBL5127116 | 0.83 | QPCT (1.00) | QPCTRXFP1RAD52ALDH1A1LMNA | |
| SCHEMBL3640787 | 0.83 | QPCT (1.00) | QPCTRXFP1RAD52ALDH1A1LMNA | |
| SCHEMBL3640847 | 0.83 | QPCT (1.00) | QPCTRXFP1RAD52ALDH1A1LMNA | |
| SCHEMBL5120880 | 0.82 | QPCT (1.00) | QPCTRXFP1RAD52ALDH1A1LMNA | |
| SCHEMBL3640158 | 0.82 | QPCT (1.00) | QPCTRXFP1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | claimed |
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | claimed |
| EP-2160389-A1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-03-10 | — | — | EP | claimed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | claimed |
| WO-2008128982-A1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | claimed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2160389-A1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-03-10 | — | — | EP | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008128982-A1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885RXFP1 171/4885RAD52 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.